期刊文献+

前列腺癌发病机制中雄激素和雄激素受体信号的作用 被引量:8

The effect of androgens and androgen receptor signaling on prostate tumorigenesis
下载PDF
导出
摘要 雄激素和雄激素受体(AR)信号在前列腺发育和腺体内环境的稳定中是必要的。AR信号几乎驱动着所有前列腺癌细胞的生长。为了驱动前列腺癌生长,在前列腺癌细胞中的AR信号功能得到完好的保留,所以,在转移性前列腺癌中的雄激素和AR信号作用得到了良好地证明。虽然雄激素和AR信号密切参与着正常前列腺的发育和晚期前列腺癌的转移,但是否雄激素和AR信号也参与了前列腺癌的发生和增殖的早期阶段,这一过程依然不明确。本文综述了前列腺组织中雄激素和AR信号的作用,以及前列腺癌从发生到转移至去势抵抗的知识,并阐述了雄激素和AR在前列腺癌启动的早期阶段中的潜在作用。 Androgen and androgen receptor ( AR) signaling is necessary in the development of prostate and the stability of gland internal environment .AR signaling drives almost all the growth of prostate cancer cells .In order to drive the growth of prostate canc-er, prostate cancer cells ’ s AR signals function kept well , we can get good proof about androgen and AR signals in metastatic pros-tate cancer.Although the androgen and AR signals is closely involved in the development of normal development of prostate and ad -vanced prostate cancer metastasis , whether it is also related to the occurrence of prostate cancer or proliferation of prostate cancer in the early stages of the process is still unknown .This review summarizes the role of androgen and and AR signaling in the prostate tis-sue , and the knowledge of prostate cancer from happening to transferring and castration resistance , as well as the potential role of an-drogen and AR signaling in the early stages of prostate cancer .
出处 《中国老年保健医学》 2015年第1期9-12,共4页 Chinese Journal of Geriatric Care
基金 国家自然科学基金(81061120527 81370445 81472408) 卫生部公益性研究基金(201302008) 国家科技部十二五支撑计划(2012BAI10B01)
关键词 雄激素 雄激素受体 前列腺癌 分子机理 androgens androgen receptor signaling prostate cancer tumorigenesis molecular mechanism
  • 相关文献

参考文献23

  • 1Siegel R, Naishadham D,Jemal A. Cancer statistics, 2013 [ J]. CA: A Cancer Jourual for Clinicians,2013,63 ( l ) : 11 - 30.
  • 2Huggins C , Clark PJ. Quantitative studies of prostatic secretion: II. The effect of castration and of estrogen injection on the normal and on the hyperplastic prostate glands of dogs [ J 1. Journal of Experimental Medicine, 1940,72 ( 6 ) :747 - 762.
  • 3Friedlander TW , Ryan CJ. Targeting the androgen receptor [ J ]. Uro- logic Clinics of North America,2012,39(4) :453 -464.
  • 4Mostaghel EA, Plymate S. New hormonal therapies for castration resist- ant prostate cancer[J]. Endocrinology and Metabolism Clinics of North America,2011,40 ( 3 ) : 625 - 642.
  • 5Dehm SM ,Tindall DJ. Alternatively spliced androgen receptor variants [ J ~. Endocrine-Related Cancer, 2011 , 18 ( 5 ) : R183 - R196.
  • 6Shiota M, Yokomizo A, Fujimoto N ,et al. Androgen receptor cofactors in prostate cancer : potential therapeutic targets of castration resistant prostate cancer [ J ]. Current Cancer Drug Targets,2011,11 ( 7 ) : 870 - 881.
  • 7Lamont KR ,Tindall DJ. Mini review: Alternative activation pathways for the androgen receptor in prostate cancer[ J]. Molecular Endocrinol- ogy,2011,25(6) :897 -907.
  • 8Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regu- lation of PI3K and androgen receptor signaling in PTEN-deficient pros- tate cancer[ J ]. Cancer Cell, 2011,19 (5) :575 - 586.
  • 9Cai C , Balk SP. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy [ J]. Endocrine-Related Cancer, 2011,18(5) :R175 - R182.
  • 10Price DK, Chan CH, Till C, et ah Androgen receptor CAG repeat length and association with prostate cancer risk : results from the pros- tate cancer prevention trial [ J 1. Journal of Urology, 2010,184 ( 6 ) : 2297 - 2302.

同被引文献114

  • 1王洛夫,江军.雄激素受体在雄激素非依赖性前列腺癌中的作用[J].第三军医大学学报,2004,26(24):2271-2273. 被引量:1
  • 2董爱生,田建明.高分辨魔角旋转磁共振波谱分析在医学中的应用[J].国外医学(临床放射学分册),2007,30(1):65-68. 被引量:1
  • 3Siegel R L,Miller K D,Jemal A.Cancer statistics,2015[J].CA Cancer J Clin,2015,65(1):5-29.
  • 4Fall K,Garmo H,Gudbjornsdottir S,et al.Diabetes mellitus and prostate cancer risk;a nationwide casecontrol study within PCBaSe Sweden[J].Cancer Epidemiol Biomarkers Prev,2013,22(6):1102-1109.
  • 5Onitilo A A,Stankowski R V,Berg R L,et al.Type 2diabetes mellitus,glycemic control,and cancer risk[J].Eur J Cancer Prev,2014,23(2):134-140.
  • 6Darbinian J A,Ferrara A M,Van Den Eeden S K,et al.Glycemic status and risk of prostate cancer[J].Cancer Epidemiol Biomarkers Prev,2008,17(3):628-635.
  • 7Barbosa-Desongles A,Hernandez C,De Torres I,et al.Diabetes protects from prostate cancer by downregulating androgen receptor:new insights from LNCaPcells and PAC120mouse model[J].PLoS One,2013,8(9):174-179.
  • 8Drake I,Wallstrom P,Hindy G,et al.TCF7L2type 2diabetes risk variant,lifestyle factors,and incidence of prostate cancer[J].Prostate,2014,74(12):1161-1170.
  • 9Wright J L,Plymate S R,Porter M P,et al.Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer[J].Prostate Cancer Prostatic Dis,2013,16(2):204-208.
  • 10Biernacka K M,Uzoh C C,Zeng L,et al.Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2[J].Endocr Relat Cancer,2013,20(5):741-751.

引证文献8

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部